Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The OZOBAX label gives no numerical cutoff. Wolf et al. recommend reduction in moderate dysfunction and avoidance in severe dysfunction or renal replacement therapy, based on case-based expert interpretation.
Before applying: Attribute the literature recommendation and evidence limits. Do not invent a reduction percentage or describe it as a product-specific trial.
Also check: Baclofen: qualitative label caution versus case-based avoidance guidance
Rxlist source
GlobalRPh RX List - OZOBAX
Product / population
Baclofen - OZOBAX oral solution; selected source sections only, not a complete prescribing monograph.
Renal measure
Qualitative renal statement; no numerical renal algorithm inferred.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
Baclofen is primarily excreted unchanged by the kidney. Use caution in renal impairment and a dose reduction may be necessary. The selected label does not define a numerical renal threshold or dose-reduction percentage. This is not evidence that standard dosing is safe in advanced kidney disease. Keep this oral solution distinct from other concentrations and intrathecal administration; review the separately attributed toxicity literature.
Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-09. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Baclofen toxicity in kidney disease - case-based expert recommendations
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Baclofen toxicity in kidney disease - case-based expert recommendations; selected source sections only, not a complete prescribing monograph.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
guideline difference
Baclofen: qualitative label caution versus case-based avoidance guidance
The OZOBAX label gives no numerical cutoff. Wolf et al. recommend reduction in moderate dysfunction and avoidance in severe dysfunction or renal replacement therapy, based on case-based expert interpretation.
How to use this: Attribute the literature recommendation and evidence limits. Do not invent a reduction percentage or describe it as a product-specific trial.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - OZOBAX
Baclofen - OZOBAX oral solution; selected source sections only, not a complete prescribing monograph.
Method: Qualitative renal statement; no numerical renal algorithm inferred.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
GlobalRPh-hosted RX List · Baclofen - OZOBAX oral solution; selected source sections only, not a complete prescribing monograph.
Renal method: Qualitative renal statement; no numerical renal algorithm inferred. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-09
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Baclofen is primarily excreted unchanged by the kidney. Use caution in renal impairment and a dose reduction may be necessary. The selected label does not define a numerical renal threshold or dose-reduction percentage. This is not evidence that standard dosing is safe in advanced kidney disease. Keep this oral solution distinct from other concentrations and intrathecal administration; review the separately attributed toxicity literature.
RDM49-rxlist-baclofen-ozobax-58ca7b86ac-C1 · Source locator: Use in Specific Populations: renal impairment, lines 181-183.
Wolf et al. / American Journal of Kidney Diseases · Baclofen toxicity in kidney disease - case-based expert recommendations; selected source sections only, not a complete prescribing monograph.
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Wolf and colleagues recommend reducing baclofen in eGFR 30-60 mL/min/1.73 m2 and avoiding it below 30 or during renal replacement therapy. Their teaching case describes severe toxicity in a hemodialysis patient. This is case-based expert guidance, not an OZOBAX-specific trial or a validated numerical dose table. The abstract does not specify a reduction percentage; none is supplied here.
Additional summaries stored on this page: 0 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.